Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies

scientific article published on 01 February 2011

Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1177/0961203310395803
P698PubMed publication ID21303837

P50authorMunther A. KhamashtaQ73418907
Guillermo Ruiz-IrastorzaQ37830875
Vittorio PengoQ42778559
Maria G TektonidouQ57034988
P2093author name stringS Machin
M Crowther
D Erkan
R Brey
S Krilis
M J Cuadrado
S Pierangeli
R Derksen
I Ruiz-Arruza
P433issue2
P921main subjectthrombosisQ261327
P304page(s)206-218
P577publication date2011-02-01
P1433published inLupusQ6704846
P1476titleEvidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies
P478volume20

Reverse relations

cites work (P2860)
Q54982015A case of extreme weight loss due to mesenteric ischemia and antiphospholipid syndrome.
Q90446471A challenging case of neuropsychiatric systematic lupus erythematosus with recurrent antiphospholipid- related stroke: A case report and literature review
Q55279180A importância de reconhecer a síndrome antifosfolípide na medicina vascular.
Q96306532ADRENAL INSUFFICIENCY SECONDARY TO BILATERAL ADRENAL HEMORRHAGE ASSOCIATED WITH ANTIPHOSPHOLIPID SYNDROME
Q96304889An update on the management of antiphospholipid syndrome
Q92639094Anaesthetic considerations for patients with antiphospholipid syndrome undergoing non-cardiac surgery
Q30355477Antiphospholipid Antibodies and Recurrent Thrombotic Events: Persistence and Portfolio.
Q59808719Antiphospholipid Syndrome and the Neurologist: From Pathogenesis to Therapy
Q33768066Antiphospholipid Syndrome: Multiple Manifestations in a Single Patient-A High Suspicion Is Still Needed
Q46466244Antiphospholipid antibodies in renal allograft recipients.
Q52368982Antiphospholipid antibodies induce thrombosis by PP2A activation via apoER2-Dab2-SHC1 complex formation in endothelium.
Q93140231Antiphospholipid antibody levels in early systemic lupus erythematosus: are they associated with subsequent mortality and vascular events?
Q30235423Antiphospholipid syndrome
Q64046338Antiphospholipid syndrome
Q91390119Antiphospholipid syndrome - an update
Q58602902Antiphospholipid syndrome: state of the art on clinical practice guidelines
Q57689029Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid antibodies
Q94327168Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid antibodies
Q24185949Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
Q47884958Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome.
Q47093647Cavernous sinus thrombosis in a patient with nephrotic syndrome.
Q38686357Childhood Lupus--Diagnosis and Management
Q60949185Clinical Phenotype of a First Unprovoked Acute Pulmonary Embolism Associated with Antiphospholipid Antibody Syndrome
Q97426362Comparison of the Therapeutic Effects of Rivaroxaban Versus Warfarin in Antiphospholipid Syndrome: A Systematic Review
Q33423959Current treatment of antiphospholipid syndrome: lights and shadows
Q47982275Diagnosis and management of the antiphospholipid syndrome
Q33421814Difficult clinical situations in the antiphospholipid syndrome
Q51252221Discontinuation of anticoagulation or antiaggregation treatment may be safe in patients with primary antiphospholipid syndrome when antiphospholipid antibodies became persistently negative.
Q38089684Duration of anticoagulation treatment for thrombosis in APS: is it ever safe to stop?
Q58783569Extensive abdominal wall ulceration as a late manifestation of antiphospholipid syndrome: a case report
Q22306331Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association
Q36087118Identification of a Monoclonal Antibody That Attenuates Antiphospholipid Syndrome-Related Pregnancy Complications and Thrombosis
Q90115791Idiopathic Normal Pressure Hydrocephalus - What We Know
Q36484399Immunotherapies for Neurological Manifestations in the Context of Systemic Autoimmunity
Q57115414Improvement of Cardiac Vegetations in Antiphospholipid Syndrome with Enoxaparin and Corticosteroids after Rivaroxaban Failure
Q37522782Improving outcomes in patients with lupus and end-stage renal disease
Q97520328Inferior vena cava filter - comprehensive overview of current indications, techniques, complications and retrieval rates
Q34462703Inferior vena cava filters: current best practices
Q36302245Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis
Q37977481Late-onset systemic lupus erythematosus: epidemiology, diagnosis and treatment
Q48328781Length of exposure to antiphospholipid antibodies, rather than age, is a risk factor for thrombosis: a retrospective single-centre observational study
Q36033553Liver transplantation in a patient with primary antiphospholipid syndrome and Budd-Chiari syndrome
Q39608521Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome
Q26774815Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives
Q37959314Management of obstetric antiphospholipid syndrome
Q38180647Management of recurrent thrombosis in antiphospholipid syndrome
Q49968681Mechanisms and management of thrombosis and bleeding in antiphospholipid syndrome
Q90412368New therapeutic strategies in systemic lupus erythematosus management
Q58551653Obstetric antiphospholipid syndrome
Q89986376Pediatric APS: State of the Art
Q41100232Pediatric antiphospholipid syndrome
Q89724842Precision medicine and the antiphospholipid syndrome: what is the future?
Q90115787Pregnancy Management in Women with Antiphospholidic Syndrome
Q60954866Prevalence and Significance of Non-conventional Antiphospholipid Antibodies in Patients With Clinical APS Criteria
Q38794847Prevention of Recurrent Thrombosis in Antiphospholipid Syndrome: Different from the General Population?
Q39027911Prevention of thrombosis in antiphospholipid syndrome
Q52649404Primary antiphospholipid syndrome presenting with homonymous quadrantanopsia.
Q64088190Recurrent Stroke Due to Antiphospholipid Syndrome Remitted by Immunotherapy, Not by Anticoagulation Therapy: A Case Report and Literature Review
Q89777587Recurrent thrombosis in patients with antiphospholipid antibodies and arterial thrombosis on antithrombotic therapy
Q55710004Recurrent thrombosis in patients with antiphospholipid antibodies treated with vitamin K antagonists or rivaroxaban.
Q87467570Renal involvement in antiphospholipid syndrome
Q38838855Renal involvement in primary antiphospholipid syndrome
Q38374309Reviewing the recommendations for lupus in children
Q33428599Right Atrial Thrombosis in Antiphospholipid Syndrome with Secondary Immune Thrombocytopenia
Q37230504Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial
Q89924903Role of direct oral anticoagulants in patients with kidney disease
Q26775647Sarcoidosis and Antiphospholipid Syndrome: A Systematic Review of Cases
Q89453447Seronegative antiphospholipid syndrome: refining the value of "non-criteria" antibodies for diagnosis and clinical management
Q45168417Splenic infarction, warm autoimmune hemolytic anemia and antiphospholipid antibodies in a patient with infectious mononucleosis
Q38097749Statins and autoimmunity
Q92737863Subarachnoid Hemorrhage After Ischemic Stroke Associated with Systemic Lupus Erythematosus and Antiphospholipid Syndrome
Q55282858Systemic Lupus Erythematosus in Primary Care: An Update and Practical Messages for the General Practitioner.
Q59807283The Differences Between Childhood and Adult Onset Antiphospholipid Syndrome
Q96135566The Issue of the Antiphospholipid Antibody Syndrome
Q38374306The journey of antiphospholipid antibodies from cellular activation to antiphospholipid syndrome
Q37959884The management of stroke in antiphospholipid syndrome
Q50906356The significance of antiphospholipid antibodies in liver recipients.
Q37347979Thrombin generation as marker to estimate thrombosis risk in patients with abnormal test results in lupus anticoagulant routine diagnostics
Q36981341Thrombotic antiphospholipid syndrome shows strong haplotypic association with SH2B3-ATXN2 locus
Q35621012Treatment of Thrombotic Antiphospholipid Syndrome: The Rationale of Current Management-An Insight into Future Approaches
Q35308972Treatment of the antiphospholipid syndrome
Q93047783Triple Antiphospholipid (aPL) Antibodies Positivity Is Associated With Pregnancy Complications in aPL Carriers: A Multicenter Study on 62 Pregnancies
Q52654857Update on Antiphospholipid Syndrome: Ten Topics in 2017.
Q35187737Venous thromboembolism and antithrombotic therapy in pregnancy
Q90416101[Antiphospholipid syndrome : Update on diagnostics and management]
Q87078561[Antiphospholipid syndrome]
Q87831212[Antiphospholipid syndrome]
Q86911419[Primary antiphospholipid syndrome: newly developed leg ulcer and history of stroke]

Search more.